The European Patent Office granted patent EP3725804A1 to Kyowa Kirin Co., Ltd. on March 25, 2026, covering an anti-BMP10 (Bone Morphogenetic Protein 10) antibody for treating hypertension and hypertensive diseases. The patent includes claims under IPC classification C07K 16/22 (immunoglobulins/antibodies) and A61P 9/12 (antihypertensives), with designated states covering all EPC contracting states including DE, FR, GB, IT, NL, and 28 other European jurisdictions.

Pharmaceutical companies developing antibody therapeutics targeting BMP10 or hypertension indications should review this patent for freedom-to-operate implications and potential blocking effects on competing programs. Companies should assess whether their research activities fall within the scope of the granted claims or qualify for research exemptions under applicable national laws.